+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Acromegaly Treatment Market Size, Share & Trends Analysis Report by Drug Type (Somatostatin Analogs, GHRA), End-use (Hospitals & Clinics), Region, and Segment Forecasts, 2023-2030

  • PDF Icon

    Report

  • 100 Pages
  • December 2023
  • Region: Global
  • Grand View Research
  • ID: 5921043
Description Jump to:
The global acromegaly treatment market size is expected to reach USD 1.93 billion by 2030, expanding at a CAGR of 5.7% from 2023 to 2030. Increasing incidence of the acromegaly disease is expected to drive the growth. For instance, the disease prevalence increased fourfold in 2015 from its previous year 2014, according to a report by the Endocrine Society. Moreover, growing investment in clinical trials by various pharmaceutical companies to develop new molecules is another factor propelling the market growth.

Furthermore, strong pipeline of drugs is anticipated to create growth opportunities in the forthcoming years. For instance, Mycapssa by Chiasma Inc. received approval in Europe in 2016. In 2018, Antisense Therapeutics launched their new formulation ALT1103 in U.S. ISIS 766720 by Ionis Pharmaceuticals Inc., a growth hormone receptor antagonist is currently under phase II clinical trial and is expected to be finished by December 2019.

The strong pipeline of drugs for somatostatin analogs is expected to propel growth of the acromegaly treatment market in near future. For instance, in 2018 around 30 clinical trials were being conducted in North America and many are waiting for the U.S. Food and Drug Administration (FDA) approval.

Acromegaly Treatment Market Report Highlights

  • Somatostatin analogs segment is expected to emerge as the largest product segment in terms of revenue share in the forthcoming years, owing to easy availability and cost-effective treatment procedure of the product
  • Hospital and clinics end use segment accounted for the largest market share as all the surgical procedures are performed in these facilities. Easy availability of surgeons Is anticipated to further drive the segment
  • North America held the dominant market share in 2022, due to favorable government insurance policies and increased investment in R&D by the pharmaceutical companies. For instance, In May 2018, U.S. Congress approved the Right to Try bill, wherein patients can try unproven medical therapeutics in case of serious illness including orphan diseases like acromegaly


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Drug Type
1.1.2. End use
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. Internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug type outlook
2.2.2. End use outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Acromegaly Treatment Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Acromegaly Treatment Market Analysis Tools
3.4.1. Industry Analysis - Porter’s Five Forces
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Acromegaly Treatment Market: Drug Type Estimates & Trend Analysis
4.1. Acromegaly Treatment Market: Key Takeaways
4.2. Acromegaly Treatment Market: Drug Type Movement & Market Share Analysis, 2022 & 2030
4.3. Somatostatin analogs
4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. GHRA
4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Others
4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Acromegaly Treatment Market: End-use Estimates & Trend Analysis
5.1. Acromegaly Treatment Market: Key Takeaways
5.2. Acromegaly Treatment Market: End-use Movement & Market Share Analysis, 2022 & 2030
5.3. Hospitals & Clinics
5.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Others
5.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Acromegaly Treatment Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Acromegaly Treatment Market by Region: Key Marketplace Takeaways
6.3. North America
6.3.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.5. Asia-Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. Novartis AG
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Ipsen Pharma
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. SUN PHARMACEUTICAL INDUSTRIES LTD.
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Chiasma, Inc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Peptron, Inc.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. WOCKHARDT
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Dauntless Pharmaceuticals
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Pfizer Inc.
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Ionis Pharmaceuticals, Inc.
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
List of Tables
Table 1 List of Abbreviations
Table 2 North America acromegaly treatment market, by drug type, 2018-2030 (USD Million)
Table 3 North America acromegaly treatment market, by end use, 2018-2030 (USD Million)
Table 4 North America acromegaly treatment market, by region, 2018-2030 (USD Million)
Table 5 U.S. acromegaly treatment market, by drug type, 2018-2030 (USD Million)
Table 6 U.S. acromegaly treatment market, by end use, 2018-2030 (USD Million)
Table 7 Canada acromegaly treatment market, by drug type, 2018-2030 (USD Million)
Table 8 Canada acromegaly treatment market, by end use, 2018-2030 (USD Million)
Table 9 Europe acromegaly treatment market, by drug type, 2018-2030 (USD Million)
Table 10 Europe acromegaly treatment market, by end use, 2018-2030 (USD Million)
Table 11 Europe acromegaly treatment market, by region, 2018-2030 (USD Million)
Table 12 Germany acromegaly treatment market, by drug type, 2018-2030 (USD Million)
Table 13 Germany acromegaly treatment market, by end use, 2018-2030 (USD Million)
Table 14 UK acromegaly treatment market, by drug type, 2018-2030 (USD Million)
Table 15 UK acromegaly treatment market, by end use, 2018-2030 (USD Million)
Table 16 France acromegaly treatment market, by drug type, 2018-2030 (USD Million)
Table 17 France acromegaly treatment market, by end use, 2018-2030 (USD Million)
Table 18 Italy acromegaly treatment market, by drug type, 2018-2030 (USD Million)
Table 19 Italy acromegaly treatment market, by end use, 2018-2030 (USD Million)
Table 20 Spain acromegaly treatment market, by drug type, 2018-2030 (USD Million)
Table 21 Spain acromegaly treatment market, by end use, 2018-2030 (USD Million)
Table 22 Sweden acromegaly treatment market, by drug type, 2018-2030 (USD Million)
Table 23 Sweden acromegaly treatment market, by end use, 2018-2030 (USD Million)
Table 24 Norway acromegaly treatment market, by drug type, 2018-2030 (USD Million)
Table 25 Norway acromegaly treatment market, by end use, 2018-2030 (USD Million)
Table 26 Denmark acromegaly treatment market, by drug type, 2018-2030 (USD Million)
Table 27 Denmark acromegaly treatment market, by end use, 2018-2030 (USD Million)
Table 28 Asia-Pacific acromegaly treatment market, by drug type, 2018-2030 (USD Million)
Table 29 Asia-Pacific acromegaly treatment market, by end use, 2018-2030 (USD Million)
Table 30 Asia-Pacific acromegaly treatment market, by region, 2018-2030 (USD Million)
Table 31 China acromegaly treatment market, by drug type, 2018-2030 (USD Million)
Table 32 China acromegaly treatment market, by end use, 2018-2030 (USD Million)
Table 33 Japan acromegaly treatment market, by drug type, 2018-2030 (USD Million)
Table 34 Japan acromegaly treatment market, by end use, 2018-2030 (USD Million)
Table 35 India acromegaly treatment market, by drug type, 2018-2030 (USD Million)
Table 36 India acromegaly treatment market, by end use, 2018-2030 (USD Million)
Table 37 Australia acromegaly treatment market, by drug type, 2018-2030 (USD Million)
Table 38 Australia acromegaly treatment market, by end use, 2018-2030 (USD Million)
Table 39 Thailand acromegaly treatment market, by drug type, 2018-2030 (USD Million)
Table 40 Thailand acromegaly treatment market, by end use, 2018-2030 (USD Million)
Table 41 South Korea acromegaly treatment market, by drug type, 2018-2030 (USD Million)
Table 42 South Korea acromegaly treatment market, by end use, 2018-2030 (USD Million)
Table 43 Latin America acromegaly treatment market, by drug type, 2018-2030 (USD Million)
Table 44 Latin America acromegaly treatment market, by end use, 2018-2030 (USD Million)
Table 45 Latin America acromegaly treatment market, by region, 2018-2030 (USD Million)
Table 46 Brazil acromegaly treatment market, by drug type, 2018-2030 (USD Million)
Table 47 Brazil acromegaly treatment market, by end use, 2018-2030 (USD Million)
Table 48 Mexico acromegaly treatment market, by drug type, 2018-2030 (USD Million)
Table 49 Mexico acromegaly treatment market, by end use, 2018-2030 (USD Million)
Table 50 Argentina acromegaly treatment market, by drug type, 2018-2030 (USD Million)
Table 51 Argentina acromegaly treatment market, by end use, 2018-2030 (USD Million)
Table 52 Middle East and Africa acromegaly treatment market, by drug type, 2018-2030 (USD Million)
Table 53 Middle East and Africa acromegaly treatment market, by end use, 2018-2030 (USD Million)
Table 54 Middle East and Africa acromegaly treatment market, by region, 2018-2030 (USD Million)
Table 55 South Africa acromegaly treatment market, by drug type, 2018-2030 (USD Million)
Table 56 South Africa acromegaly treatment market, by end use, 2018-2030 (USD Million)
Table 57 Saudi Arabia acromegaly treatment market, by drug type, 2018-2030 (USD Million)
Table 58 Saudi Arabia acromegaly treatment market, by end use, 2018-2030 (USD Million)
Table 59 UAE acromegaly treatment market, by drug type, 2018-2030 (USD Million)
Table 60 UAE acromegaly treatment market, by end use, 2018-2030 (USD Million)
Table 61 Kuwait acromegaly treatment market, by drug type, 2018-2030 (USD Million)
Table 62 Kuwait acromegaly treatment market, by end use, 2018-2030 (USD Million)
List of Figures
Figure 1 Market research processes
Figure 2 Data triangulation techniques
Figure 3 Primary research pattern
Figure 4 Market research approaches
Figure 5 Value-chain-based sizing & forecasting
Figure 6 QFD modeling for market share assessment
Figure 7 Market formulation & validation
Figure 8 Acromegaly treatment: Market outlook
Figure 9 Acromegaly treatment: Competitive insights
Figure 10 Parent market outlook
Figure 11 Related/ancillary market outlook
Figure 12 Penetration and growth prospect mapping
Figure 13 Industry value chain analysis
Figure 14 Acromegaly treatment market driver impact
Figure 15 Acromegaly treatment market restraint impact
Figure 16 Acromegaly treatment market strategic initiatives analysis
Figure 17 Acromegaly treatment market: Drug type movement analysis
Figure 18 Acromegaly treatment market: Drug type outlook and key takeaways
Figure 19 Somatostatin analogs market estimates and forecasts, 2018-2030 (USD Million)
Figure 20 GHRA market estimates and forecasts, 2018-2030 (USD Million)
Figure 21 Others market estimates and forecasts, 2018-2030 (USD Million)
Figure 22 Acromegaly treatment market: End use movement analysis
Figure 23 Acromegaly treatment market: End use outlook and key takeaways
Figure 24 Hospital & clinics market estimates and forecasts, 2018-2030 (USD Million)
Figure 25 Others market estimates and forecasts, 2018-2030 (USD Million)
Figure 26 Global acromegaly treatment market: Regional movement analysis
Figure 27 Global acromegaly treatment market: Regional outlook and key takeaways
Figure 28 North America market estimates and forecasts, 2018-2030 (USD Million)
Figure 29 U.S. market estimates and forecasts, 2018-2030 (USD Million)
Figure 30 Canada market estimates and forecasts, 2018-2030 (USD Million)
Figure 31 Europe market estimates and forecasts, 2018-2030 (USD Million)
Figure 32 UK market estimates and forecasts, 2018-2030 (USD Million)
Figure 33 Germany market estimates and forecasts, 2018-2030 (USD Million)
Figure 34 France market estimates and forecasts, 2018-2030 (USD Million)
Figure 35 Italy market estimates and forecasts, 2018-2030 (USD Million)
Figure 36 Spain market estimates and forecasts, 2018-2030 (USD Million)
Figure 37 Sweden market estimates and forecasts, 2018-2030 (USD Million)
Figure 38 Norway market estimates and forecasts, 2018-2030 (USD Million)
Figure 39 Denmark market estimates and forecasts, 2018-2030 (USD Million)
Figure 40 Asia-Pacific market estimates and forecasts, 2018-2030 (USD Million)
Figure 41 Japan market estimates and forecasts, 2018-2030 (USD Million)
Figure 42 China market estimates and forecasts, 2018-2030 (USD Million)
Figure 43 India market estimates and forecasts, 2018-2030 (USD Million)
Figure 44 Australia market estimates and forecasts, 2018-2030 (USD Million)
Figure 45 Thailand market estimates and forecasts, 2018-2030 (USD Million)
Figure 46 South Korea market estimates and forecasts, 2018-2030 (USD Million)
Figure 47 Latin America market estimates and forecasts, 2018-2030 (USD Million)
Figure 48 Brazil market estimates and forecasts, 2018-2030 (USD Million)
Figure 49 Mexico market estimates and forecasts, 2018-2030 (USD Million)
Figure 50 Argentina market estimates and forecasts, 2018-2030 (USD Million)
Figure 51 Middle East and Africa market estimates and forecasts, 2018-2030 (USD Million)
Figure 52 Saudi Arabia market estimates and forecasts, 2018-2030 (USD Million)
Figure 53 South Africa market estimates and forecasts, 2018-2030 (USD Million)
Figure 54 UAE market estimates and forecasts, 2018-2030 (USD Million)
Figure 55 Kuwait market estimates and forecasts, 2018-2030 (USD Million)

Companies Mentioned

  • Novartis AG
  • Ipsen Pharma
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • Chiasma, Inc.
  • Peptron, Inc.
  • WOCKHARDT
  • Dauntless Pharmaceuticals
  • Pfizer Inc.
  • Ionis Pharmaceuticals, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedDecember 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 1.26 Billion
Forecasted Market Value ( USD ) by 2030 $ 1.93 Billion
Compound Annual Growth Rate5.7%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

Global Acromegaly Treatment Market by Disease Type (Ectopic Acromegaly, Pseudo Acromegaly), Drug Class (Bromocriptine Mesylate (Parlodel), Dopamine Agonists, Growth Hormone Receptor Antagonist), Distribution Channel, End-User - Forecast 2024-2030 - Product Image

Global Acromegaly Treatment Market by Disease Type (Ectopic Acromegaly, Pseudo Acromegaly), Drug Class (Bromocriptine Mesylate (Parlodel), Dopamine Agonists, Growth Hormone Receptor Antagonist), Distribution Channel, End-User - Forecast 2024-2030

  • Report
  • 194 Pages
  • Global
From
Somatostatin Analogs Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Somatostatin Analogs Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Global Somatostatin Analogs Market by Type (Lanreotide, Octreotide, Pasireotide), Application (Acromegaly, Neuroendocrine Tumors) - Forecast 2023-2030 - Product Image

Global Somatostatin Analogs Market by Type (Lanreotide, Octreotide, Pasireotide), Application (Acromegaly, Neuroendocrine Tumors) - Forecast 2023-2030

  • Report
  • 196 Pages
  • Global
From
Acromegaly Treatment Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2028F - Product Image

Acromegaly Treatment Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2028F

  • Report
  • 182 Pages
  • Global
From
Acromegaly Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Acromegaly Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 75 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.